Podcasts about Drug design

What if the biggest challenge of our time isn't living longer, but living better? In this episode, we're tackling one of humanity's greatest accomplishments—and perhaps its most overlooked challenge: longevity. As more people live past 100, our systems—healthcare, finance, career planning, and even our cultural perceptions of aging—need a fundamental overhaul. We're joined by Dr. Andrew Scott, author of The Longevity Imperative, and Vijay Pande a16z's Bio & Health general partner, to explore how a shift from “sick care” to “health care” could transform our lives. Together, we discuss the implications of longer lifespans, from the individual choices that can improve our healthspans to the economic and societal shifts required to sustain a healthier, more productive aging society. Join us as we reimagine the future of aging, where living to 100 can be more than survival—it can be a life well-lived. Resources: Find Andrew on X: https://x.com/profandrewscott?lang=enFind Vijay on X: https://x.com/vijaypandeLearn more about The Longevity Imperative:https://profandrewjscott.com/the-longevity-imperative/ Stay Updated: Let us know what you think: https://ratethispodcast.com/a16zFind a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Have you every wondered how exactly drugs are designed to access the brain? The answer usually revolves around one very important part of the central nervous system. The blood brain barrier is the layer of cells that protects the brain from pathogens while still allowing for the removal of toxins. From pain medications to ozempic, several drugs have been designed to get across this barrier in one way or another. In this episode, we are joined by an expert in the field and cover how the blood brain barrier works, how common drugs act on it, what can go wrong, and how you can leverage your own blood brain barrier. Dr. Sebastian Furness is from Adelaide and received his BSc(Hons) and PhD. from the University of Adelaide, in the biochemistry of gene regulation. He then did postdoctoral research on how blood stem cells regenerate all the different types of blood cells at the University of British Columbia in beautiful Vancouver before returning to Australia (this time in Melbourne) to work on the molecular functioning of an important class of drug targets called G protein-coupled Receptors. Sebastian won an ARC Future Fellowship, the most prestigious early-mid career fellowship for discovery scientists in Australia. This allowed him to develop his own research program where he moved to the University of Queensland, in sunny Brisbane. Sebastian runs a small lab that focusses on trying to understand the molecular-level details of how communication occurs between the gastrointestinal tract and brain. He teaches into undergraduate Biomedical Science and Pharmacy and enjoys communicating science in various forums, including “Pint of Science” and “The Conversation”. For more information on what the lab does see: RTClab.org AND https://biomedical-sciences.uq.edu.au/research/groups/receptor-transducer-coupling Author: Elena Koning Email: thinktwicepodcast@outlook.com Instagram: @thinktwice_podcast LinkedIN: Think Twice Podcast Patreon: https://www.patreon.com/ThinkTwicePodcast Disclaimer: Think Twice is a podcast for general information and entertainment purposes only. The content discussed in the episodes does not reflect the views of the podcast committee members or any institution they are affiliated with. The use of the information presented in this podcast is at the user's own risk and is not intended to replace professional healthcare services.

This episode is sponsored by Speechmatics. Check it out at www.speechmatics.com/realtime     In this episode of the Eye on AI podcast, host Craig Smith sits down with Thomas G. Dietterich, a pioneer in the field of machine learning, to explore the evolving landscape of AI and its application in real-world problems.   Thomas shares his journey from the early days of AI, where rule-based systems dominated, to the breakthroughs in deep learning that have revolutionized computer vision. He delves into the challenges of detecting novelty in AI, emphasizing the importance of teaching machines to recognize "unknown unknowns."   The conversation highlights the growing field of computational sustainability, where AI is used to solve pressing environmental problems, from designing new materials to optimizing wildfire management. Thomas also provides insights into the role of transformers and generative AI, discussing their power and limitations, particularly in tasks like object recognition and problem formulation.   Join us for a deep dive into the future of AI, where Thomas explains why the development of novel materials and drugs may have the most transformative impact on our economy. Plus, hear about his latest work on multi-instance learning, weak supervision, and the role of reinforcement learning in real-world applications like wildfire management.   Don't forget to like, subscribe, and hit the notification bell to stay updated on the latest trends and insights in AI and machine learning!     Stay Updated: Craig Smith Twitter: https://twitter.com/craigss Eye on A.I. Twitter: https://twitter.com/EyeOn_AI     (00:00) Introduction to Thomas Dietterich's Machine Learning Journey (02:34) The Early Days of Machine Learning and AI Systems (04:29) Tackling the Multiple Instance Problem in Drug Design (05:41) AI in Sustainability (07:17) The Challenge of Novelty Detection in AI Systems (08:00) Addressing the Open Set Problem in Cybersecurity and Computer Vision (09:11) The Evolution of Deep Learning in Computer Vision (11:21) How Deep Learning Handles Novel Representations (12:01) Foundation Models and Self-Supervised Learning (14:11) Vision Transformers vs. Convolutional Neural Networks (16:05) The Role of Multi-Instance Learning in Weakly Labeled Data (18:36) Ensemble Learning and Deep Networks in Machine Learning (20:33) The Future of AI: Large Language Models and Their Applications (23:51) Symbolic Regression and AI's Role in Scientific Discovery (34:44) AI in Wildfire Management: Using Reinforcement Learning (39:32) AI-Driven Problem Formulation and Optimization in Industry (41:30) The Future of AI Reasoning Systems and Problem Solving (45:03) The Limits of Large Language Models in Scientific Research (50:12) Closing Thoughts: Open Challenges and Opportunities in AI  

Michael Crackower, PhD, Chief Scientific Officer of Ventus Therapeutics, and Jason Burch, PhD, join Vineeta Agarwala, MD, PhD, general partner at a16z Bio + Health.Together, they talk about how Ventus approaches drug discovery and why they believe we're in the early stages of small molecule innovation. Specifically, we'll hear about the ReSOLVE platform, which enables the drug hunting team to more accurately design and iterate on small molecular compounds for therapeutic applications. They also talk about the current candidates in the pipeline and how they're able to go from idea to IND in record time. 

Drug Design, proteins, small molecules

Tune into this month's episode of the Scope of Things, where host Deborah Borfitz covers the use of AI for trial screening and recruitment purposes, a diabetes drug that may help treat sleep apnea, questionable advice from the FDA given to departing staffers, why the entire clinical trial enterprise may need to be revamped to eliminate systemic biases, and more. Hannah Kemp, vice president of strategic client engagement at Surgo Health, also joins the conversation to talk about how Surgo Health is helping companies recruit participants and her SCOPE 2024 presentation, as well as her thoughts on patient-focused drug design and the challenge of getting study sponsors on-board with enrollment strategies. 

On this episode, I was joined by Alan Stevens and Rumi Young who walk through the contents of the FDA Draft Essential Drug Delivery Outputs for Devices Intended toDeliver Drugs and Biological Products Guidance for Industry. Industry Comments are DUE 9/29/2024. Alan Stevens is the Global Head of Complex Devices and Drug Delivery Systems at AbbVie within the RA Emerging Technologies, Devices and Combination Products team. Prior to joining AbbVie, Alan spent 20 years at the FDA/CDRH leading premarket review and policy development for drug delivery devices and combination products. Rumi Young, Meng, RAC is the Director of Regulatory Policy at Novo Nordisk. Rumi joined Industry from FDA where she spent four years in CDRH's Division of Drug Delivery, General Hospital and Human Factors. As Acting Assistant Director for Injection Devices, her team was responsible for the approval of drug delivery injection devices and combination products such as syringes, auto injectors, pen injectors, on-body injectors and smart connected devices. Prior to FDA Rumi worked at Genentech and AstraZeneca for eight years in combination product development. Rumi has both a Bachelors in Chemistry and Chemical Biology and Masters in Engineering in Material Science from Cornell University.

Losing your hair? Discover the truth about hair loss remedies and learn evidence-based strategies for healthier hair in this episode of Heal Thy Self with Dr. Christian Gonzalez. Explore the science behind hair loss, debunk common myths, and provide a comprehensive approach to maintaining and improving your hair health. Show Notes: -Hair Loss Overview, Statistics, and Prevalence -Common types of Hair Loss: Androgenetic Alopecia, Telogen Effluvium, Alopecia Areata, Anagen Effluvium -Types of Treatments: Conventional (Minoxidil, Finasteride, Hair Transplants); Emerging (PRP, LLLT, Stem Cell Therapy); Holistic Approaches (Nutrition, Stress management, and Exercise benefits) -Supplements, Herbal options and Natural Remedies like onion juice, castor oil, and rosemary oil === Thank you to our Sponsors! Puori https://puori.com/drg and use code DRG for 20% off. OurPlace https://fromourplace.com and use code DRG to receive 10% off. === References: Otberg, N., Finner, A. M., & Shapiro, J. (2007). Androgenetic alopecia. Endocrinology and Metabolism Clinics of North America, 36(2), 379-398. Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy, 13, 2777-2786. Rossi, A., Anzalone, A., Fortuna, M. C., Caro, G., Garelli, V., Pranteda, G., & Carlesimo, M. (2016). Multi-therapies in androgenetic alopecia: review and clinical experiences. Dermatologic Therapy, 29(6), 424-432. Gentile, P., Garcovich, S., Bielli, A., Scioli, M. G., Orlandi, A., & Cervelli, V. (2015). The effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial. Stem Cells Translational Medicine, 4(11), 1317-1323. Guo, E. L., & Katta, R. (2017). Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatology Practical & Conceptual, 7(1), 1-10. Sharquie, K. E., & Al‐Obaidi, H. K. (2002). Onion juice (Allium cepa L.), a new topical treatment for alopecia areata. The Journal of Dermatology, 29(6), 343-346. Panahi, Y., Taghizadeh, M., Marzony, E. T., & Sahebkar, A. (2015). Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed, 13(1), 15-21.

Surge Biswas is the cofounder and CEO of Nabla Bio, an AI platform to enable precise drug design and high-throughput measurement of drug properties. They recently raised $26M Series A led by Radical Ventures. He has a PhD in Bioinformatics and Integrative Genomics from Harvard University. Surge's favorite book: Permutation City (Author: Greg Egan)(00:01) Introduction(00:07) Generative AI in Drug Design(01:19) Traditional vs. AI-driven Drug Discovery(03:42) Designing Antibodies(05:06) Therapeutic Antibodies Design Process(07:39) Data Sets for AI in Drug Discovery(10:48) High Throughput Measurement in Drug Discovery(13:14) Setting Up High Throughput Screening Assays(18:46) Multiplexed Screens in Drug Discovery(21:55) Protein Characterization Techniques(24:33) Protein-Protein Interactions(28:12) AI in Protein Characterization(30:55) Technological Breakthroughs in AI and Bio(32:36) Rapid Fire Round(36:27) Conclusion--------Where to find Prateek Joshi: Newsletter: https://prateekjoshi.substack.com Website: https://prateekj.com LinkedIn: https://www.linkedin.com/in/prateek-joshi-91047b19 Twitter: https://twitter.com/prateekvjoshi 

Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.Together, they discuss the transformative power of drugs in changing human health—and history. They also reflect on the evolution of the drug discovery process as it shifts from serendipitous discovery to AI-enabled engineering. Finally, they chat about where the industry is headed, and how AI might change the competition landscape.

Welcome to Season 2 of our podcast, On the Edge with SIC! This season, we'll experiment with some shorter length, learning oriented episodes. In this episode, we review responses to our most important question from Season 1 - What does On the Edge mean to you? We've compiled 6 responses to this question from our Season 1 interviewees around the theme of knowledge and learning. As well, we share our personal insights and professional experiences on this theme. We hope you learn something from this episode that you could apply to your work, school or play in the fields of healthcare, design and the intersection between the two. Resources Clips included from Season 1 acknowledging our amazing guests - full episodes available here: https://www.sichealth.ca/podcast 1. Episode 14: Taking Care of Dying Children with Dr. Natasha Datoo 2. Episode 13: Health Services Design with Liliana Rodriguez 3. Episode 12: Systems Leadership with Peter Jones 4. Episode 9: Empathy in Drug Design with Morẹ́nikẹ́ Ẹniọlá Ọláòṣebìkan 5. Episode 7: Diversity and Inclusion with Firefly Creative Writing 6. Episode 6: Spanning the Boundaries of Impact and Evaluation with Julie Gilbert --- Send in a voice message: https://podcasters.spotify.com/pod/show/sichealth/message

In this podcast, Dan Weston, Scientific Leader, Biotransformation at GSK discusses his recent publication on the important role that Metabolite ID plays in drug discovery.The episode addresses the following questions:Why studying biotransformation is an important part of early drug design A strategy to combine in silico tools, high-resolution MS and software-assisted data analysis to optimize data delivery and qualityHow this influences medicinal chemistry and the design–make–test cycleSpeaker:Dan Weston, Ph.D.  - Scientific Leader, Biotransformation at GSKDan gained his Ph.D. in ion-trap mass spectrometry from Nottingham Trent University.  He has held positions at Unilever (environmental fate using LC-MS); Schering-Plough (US) (small-molecule Met-ID for drug discovery); Nottingham Trent University (designing and building novel ion-mobility instrumentation); AstraZeneca (Met-ID for drug development); Waters (demo chemist, utility of ion mobility for small molecule applications); Sygnature (Met-ID Team Leader); and currently at GSK (Scientific Leader; providing cross-portfolio biotransformation support). His research interests include structural elucidation using novel mass spectrometric approaches; complementary analytical techniques such as ion mobility for data rationalization and insights into metabolite structure; in silico approaches for efficient data analysis; ambient ionization and rapid sample screening techniquesReference:Weston, D.J., Dave M., Colizza K. et al., 2022. A discovery biotransformation strategy: combining in silico tools with high-resolution mass spectrometry and software-assisted data analysis for high-throughput metabolism, Xenobiotica, 52(8): 928-942Stay tuned for more podcasts in our Pharmaron DMPK Insights Series!

In this episode, we combine a wealth of information from pioneers in pharmacology & drug design ( Dr. L. Jungheim ( Former Mentor) & Dr. L.C. Campeau (Associate Vice President, Head of Small Molecule Process R&D at Merck) , bioengineering ( Dr. Robert Langer,Sc.D. - MIT Institute Professor & Co-Founder of Moderna) and designing bioisosteres ( Dr. Kevin Brown, James F. Jackson Professor of Chemistry, IU-Bloomington) ), to present salient and key insights on careers in those areas and advice and skills needed to do well in those fields. Definitely an episode worth listening to! The order of the interviews: 1. Dr. Robert Langer, Sc.D. 2. Dr. L.C. Campeau, Ph.D. 3. Dr. K. Brown, Ph.D. 4. Dr. L. Jungheim, Ph.D. -- Note: The views on this podcast represent those of my guest(s) and I.

Did you know that Empathy can be a Superpower? In this month's podcast episode, we interview Morẹ́nikẹ́ Ẹniọlá Ọláòṣebìkan, a pharmaceutical manufacturing innovator, licensed pharmacist and pharmacy owner, who embraces Empathy in Drug Design. Morẹ́nikẹ́ s Deep Empathy for others forms a strong foundation for her ventures, making her an Innovation Superhero in medication design & delivery! Listen to our brief, but entertaining conversation and connect with us to learn about how to cultivate Empathy (email: info@sichealth.ca). Resources Morẹ́nikẹ́'s ventures, collectively known as Kemet Group, is on the following social media platforms: https://www.linkedin.com/company/kemet-group/ https://www.youtube.com/@kemetglobal https://www.facebook.com/kemetpharm --- Send in a voice message: https://podcasters.spotify.com/pod/show/sichealth/message

The ‘scientific' consensus is that the Earth is some billions of years old (on the order of four-and-a-half billion years old) and that the Universe is some fourteen or so billion years old. But Scripture paints a different picture. Which may, should, or must the Christian believe? Is the contention of the so-called ‘scientific community' even reasonable? Which is to say: Does it stand up to scrutiny? Knowledge is warranted true belief, and so it is vitally important to ask upon what warrant the scientists base their beliefs. As we will show in this episode, the Christian position is — unequivocally — that the Earth is ancient in terms of created age and young (some six thousand or so years) in terms of chronological age and that God created all things in six literal, twenty-four-hour days. As to the supposedly ‘scientific' position? Well, it does not stand up particularly well under scrutiny. Subscribe to the podcast here. Show Notes Hexameron [Wikipedia] See Also “Geochronologically Speaking” “James Tour: The Origin of Life Has Not Been Explained” [YouTube] “James Tour & Stephen Meyer Bring Clarity to the Origin of Life Debate (Ep. 1)” [YouTube] Discover Science [YouTube Channel] “Copying and Pasting Passwords” (Relevant for the math involved in the latter part of the episode.) Creation.com CreationWiki.com Further Reading Cosmic background radiation [Wikipedia] DNA [Wikipedia] RNA [Wikipedia] mRNA [Wikipedia] Chirality [Wikipedia] “The Significance of Chirality in Drug Design and Development” “Nature's mirror: The code for chirality” “Understanding the Thalidomide Chirality in Biological Processes by the Self-disproportionation of Enantiomers” Amino Acid [Wikipedia] Abiogenesis [Wikipedia] Neo-Darwinism [Wikipedia] Modern Synthesis [Wikipedia] Hard Problem of Consciousness [Wikipedia] Qualia [Wikipedia] Probability [Wikipedia] Blood Clotting “How it all starts: initiation of the clotting cascade” “Coagulation Cascade” Coagulation [Wikipedia] Vision Visual Phototransduction [Wikipedia] “Phototransduction” Labeling of Fertilizer [Wikipedia] Deoxyribose [Wikipedia] Organophosphate [Wikipedia] Books Darwin's Black Box: The Biochemical Challenge to Evolution by Michael Behe Theistic Evolution: A Scientific, Philosophical, and Theological Critique edited by J. P. Moreland, et al. Also available on ChristinBook.com. Parental Warnings None.

Our experience with mRNA vaccines during the COVID pandemic showed us the possibility of  designing other RNA-based drugs in a flexible and efficient manner. Dr. Athma Pai of the UMass Chan Medical School talks about how her research into RNA therapeutics and the immense promise it holds for conquering a wide range of diseases, from. cancer to sickle cell anemia, and more.  Veteran broadcast journalists George Lewis and Judy Muller moderated the session with Dr. Pai, recorded at the Telluride Conference Center in Mountain Village, Colorado

Tune in to see Application Scientists from Nanome discuss how drug design and discovery can be improved across teams using XR. From pocket characterization to docking, and more, teams from all over the world can still come together in the space through the power of XR toolsKeita FunakawaCOONanomeKeita Funakawa is Nanome's COO. Keita's passion lies at the intersection of emerging technologies, digital arts, and science. He graduated from UC San Diego with a B.S. in Management Science (Quantitative Economics) and a minor in Visual Arts Digital Media. He co-founded Nanome in 2015 and now leads company operations.Mike BishopDrug Discovery ConsultantNanomeMike Bishop started Bishop Drug Discovery Consulting in 2019 after 26 years as a medicinal chemist with GSK. From 2001 to 2014 he directed a department of medicinal chemists and DMPK scientists with a focus on metabolic diseases, identifying ~10 clinical development candidates. From 2014 to 2019, Mike served as a Director in GSK's Discovery Partnerships with Academia (DPAc) unit, with responsibilities for thorough vetting of research opportunities across multiple therapeutic areas, building collaborative workplans and leading joint research programs with academic investigators. Mike earned a B.A. in chemistry from Rice University in Houston, TX, worked in the petrochemical industry with Amoco Chemical in Texas City, TX for two years, and then returned to Rice, earning a Ph.D. in organic chemistry under the guidance of Dr. Marco Ciufolini.Jonathon GastSenior Application ScientistNanomeJonathon Gast has a background in pharmacology, informatics, and medicinal chemistry. He completed his Ph.D. in molecular pharmacology at Purdue University with a focus on the creation of informatic approaches for the determination of mechanisms of action of synthetic lethal combinations. As an applications scientist at Nanome, he communicates with customers to understand their research objectives to create novel solutions through Nanome. This includes the creation of customized software, on-site training, or online demonstrations.

Gisbert Schneider – winner of the Ernst Schering Price 2022 – worked in various places before his professional path led him to ETH, where he now heads the Singapore-ETH Centre.

Discngine Labs: Virtual Reality for Structure-Based Drug DiscoveryEver wondered how Virtual Reality for Drug Design looks like in practice?  In the second session of our Discngine Labs, they host industry experts Wilian Cortopassi and Dr. Rishi Gupta from Novartis Institutes for BioMedical Research (NIBR) will present the “NIBR”Verse: the multidimensional space that brings together data and peers from all over the world in a single (virtual) place for effective collaborations in structure-based drug design. The presentation will be followed by the panel discussion on the current and future opportunities of Virtual Reality for Drug Discovery. Steve McCloskey, from the leading VR software company Nanome, will chair the discussion where industry experts and early adopters will share their thoughts and experiences on the topic.  Recording with video here: https://www.discngine.com/event/2022/06/23/discngine-labs-virtual-reality-for-collaborative-sbdd

Victoria Gamerman's love of analytics and math came from her grandmother—the first mathematician she knew. And in her nearly decade at Boehringer Ingelheim, she's been putting that love to use as the Global Head of Data Governance and Insights.  In the latest episode of Bio-IT World's Trends from the Trenches podcast, host Stan Gloss, founder of BioTeam, talks with Gamerman about real world data, why it's important for drug discovery, and the shifts happening around how we think about data. “Historically what I have seen and observed in terms of industry trends and trends from regulators is… a culture of data collected for a very specific purpose. Therefore, the design of a clinical trial is very specific to address the scientific question at hand,” she says.  Gamerman speaks openly about how shifts in technology help real-world data make a significant impact on precision and public health, the challenges that varied data sources present to scientists, and how those same challenges present useful information regarding a patient's health journey. “The trifecta of information that ultimately comes out of those data sources is what will give us the huge opportunity to better understand and create really powerful medicines for future generations.” Links from this episode:  Bio-IT World BioTeam Boehringer Ingelheim 

In this 58th episode of "The Weekly Bioanalysis" podcast, Dom and John wrap up their 2-part series on the Evolution of Bioanalysis, as they dive into the history of their bioanalysis careers by reviewing Drug Design and Development, and how that has effected the things CROs like KCAS do today. They discuss where the pharmaceutical and biopharmaceutical industry has been, and work their from 2010 or so to the modern day lab space - and even a bit on what the future may hold in the space."The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA and Milan, Italy, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

During the 57th episode of "The Weekly Bioanalysis" podcast, Dom and John have a chance to dive into their history of their bioanalysis careers by reviewing the evolution of Drug Design and Development, and how that has effected the things CROs like KCAS do today. They discuss where the pharmaceutical and biopharmaceutical industry has been, and work their way through to roughly 2010 or so by the end of this multi-part series (check back soon for the continued episodes as they move their way into the present day)."The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA and Milan, Italy, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.

Visit https://thermofisher.com/bctl to register for your free Bringing Chemistry to Life T-shirt and https://www.thermofisher.com/chemistry-podcast/ to access the extended video version of this episode and the  episode summary sheet, which contains links to recent publications and additional content recommendations for our guest. You can access the extended video version of this episode via our YouTube channel to hear, and see, more of the conversation!Antibiotics are an incredibly important class of drugs and possibly the most impactful, life-changing scientific innovation in history. However, microorganisms reproduce themselves very rapidly and can evolve in literal minutes. We can't iterate science this quickly, which is the basis of increasing cases of antibiotic resistance that are a growing concern in modern medicine. Antibiotics are complex both chemically and in their biological function, which makes them hard to develop and a relatively unattractive pharmaceutical class from the business perspective. Like never before, we need a fresh perspective, and this is where Ziyang Zhang is leaving an impression. Ziyang is young, but incredibly productive and creative. Even before starting with his own research group (soon at Berkley), he has achieved so much and shown incredible chemical talent and thinking unlike anyone else's. His new way of thinking can affect drug development strategies for antibiotics and beyond.This is a captivating discussion with an incredible character, that fascinates with his understated style as he introduces us to his chemistry and his ideas. In a classic BCTL way, we explore his personal and professional path, his research into macrolide antibiotics, and his novel approach to selectively targeting brain cancer.

Heart attack and stroke are leading causes of death worldwide. Current treatments are aimed at prevention-- using various medications to control the health of the circulatory system.  This week's podcast speaks with Dr. Oki O'Connor, Co-CEO of Underdog Pharmaceuticals. Dr. O'Connor discusses the cellular basis of atherosclerosis, and how modified cholesterol play a central role in its development.  We then discuss the ability of a cyclical carbohydrate called cyclodextrin to sequester cholesterol, and how this company has used computer modeling to modify cyclodextrins to limit and potentially reverse cardiovascular disease. There are also potential ramifications in Alzheimer's Disease prevention and treatment.  

In February of 2022, 8 papers were published on the topic of using neuroprotective compounds as treatment for AD. Anusha will guide you through these papers exploring the entire drug discovery pipeline, from discovery to clinical trials.  Sections in this episode:  Drug Discovery (2.01)  Drug Development (4.59)  Clinical Trials (11.58) -------------------------------------------------------------- To find the numbered bibliography with all the papers covered in this episode, click here, or use the link below:https://drive.google.com/file/d/1zzsck-2adMbZB8_cYV6B-AyOwd2p_gqt/view?usp=sharingTo access the folder with ALL our bibliographies, follow this link (it will be updated as we publish episodes and process bibliographies), or use the link below:https://drive.google.com/drive/folders/1bzSzkY9ZHzzY8Xhzt0HZfZhRG1Gq_Si-?usp=sharingYou can also find all of our bibliographies on our website: www.amindr.com. --------------------------------------------------------------Follow-up on social media for more updates!Twitter: @AMiNDR_podcastInstagram: @AMiNDR.podcastFacebook:  AMiNDR  Youtube: AMiNDR PodcastLinkedIn: AMiNDR PodcastEmail: amindrpodcast@gmail.com  -------------------------------------------------------------- Please help us spread the word about AMiNDR to your friends, colleagues, and networks! And if you could leave us a rating and/or review on your streaming app of choice (Apple Podcasts, Spotify, or wherever you listen to the podcast), that would be greatly appreciated! It helps us a lot and we thank you in advance for leaving a review! Don't forget to subscribe to hear about new episodes as they come out too. Thank you to our sponsor, the Canadian Consortium of Neurodegeneration in Aging, or CCNA, for their financial support of this podcast. This helps us to stay on the air and bring you high quality episodes. You can find out more about the CCNA on their website: https://ccna-ccnv.ca/. Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was scripted, hosted and edited by Anusha Kamesh, and reviewed by Kira Tosefsky and Ellen Koch. The bibliography was made by Anjana Rajendrani and the wordcloud was created by Sarah Louadi (www.wordart.com). Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer's Disease papers into episodes each month. For February 2022, the sorters were Sarah Louadi, Christy Yu, Ben Cornish, Eden Dubchak, Vrishali Salian, Kira Tosefsky, and Elyn Rowe. Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, and Lara Onbasi for keeping everything running smoothly.Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   -------------------------------------------------------------- If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  --------------------------------------------------------------*About AMiNDR: *  Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!" 

Our conversation with Dr. Bruce Donald, James B. Duke Professor of Computer Science, Mathematics, and Chemistry and Professor of Biochemistry and Electrical and Computer Engineering at Duke University. Dr. Donald is also the founder of Ten63 Therapeutics, whose mission to is to “Drug the Undruggable.” See more about Dr. Donald at https://users.cs.duke.edu/~brd/

Shahid took us from his desire to create drugs all the way to his new developer job in New Zealand. We spoke about his Ph.D., changing careers, discovering computers (again), making your hobby into your day job, applying, interviewing, user groups and communities, and changing jobs during a pandemic.Here are the links from the show:Twitter https://twitter.com/shahiddevLinkedIn https://www.linkedin.com/in/shahiddevBlog https://blog.headforcloud.comPlaylist of some of Shahid's talks https://www.youtube.com/channel/UCQYoE2x33iz8LeqhzWA4BUQ/playlistsAuror's careers page https://www.auror.co/company-careersShahid's first programming language: BBC micro and the turtle - https://dev.to/mattwarren/exploring-the-bbc-microbit-software-stack-and-os-b11CreditsCover Campfire Rounds by Blue Dot Sessions is licensed CC BY-NC-ND 4.0.Your host is Timothée (Tim) Bourguignon, more about him at timbourguignon.fr.Gift the podcast a rating on one of the major platforms https://devjourney.info/subscribeSupport the podcast, support us on Patreon: https://bit.ly/devjpatreonSupport the show (http://bit.ly/2yBfySB)

Alexander is currently a postdoc as a member of the personalized medicine cluster in Copenhagen and at the Institute of Biological Psychiatry in Roskilde working with the UK Biobank and other large-scale population cohorts. Alexander has a big interest in the integration of large biomedical data in genomics, structural biology, pharmacology, and pharmacoepidemiology with innovative computational methods to gain novel insights into receptor biology. During his Ph.D. with David Gloriam at the Department of Drug Design and Pharmacology in Copenhagen, he worked on novel analytical methods to identify human signaling systems and thereby discovered endogenous peptides activating several orphan receptors. Alexander had a research sabbatical with Madan Babu at the MRC Laboratory of Molecular Biology in Cambridge, UK, where he was working on the impact of genetic variations on drug response. He received the “HC Ørsted Research talent prize” and “Bayer Pharmaceuticals Ph.D. Award” for his work on GPCRs. ------------------------------------------- Imagine a world in which the vast majority of us are healthy. The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together. To build our #GPCR Ecosystem, we created various enabling outlets. For more details, visit our website http://www.DrGPCR.com/Ecosystem/. Are you a #GPCR professional? - Register to become a Virtual Cafe speaker http://www.drgpcr.com/virtual-cafe/ - Subscribe to our Monthly Newsletter http://www.drgpcr.com/newsletter/ - Listen and subscribe to #DrGPCR Podcasts http://www.drgpcr.com/podcast/ - Support #DrGPCR Ecosystem with your Donation. http://www.drgpcr.com/sponsors/ - Reserve your spots for the next #DrGPCR Virtual Cafe http://www.drgpcr.com/virtual-cafe/ - Watch recorded #DRGPCR Virtual Cafe presentations: https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw - Bring in a #GPCR Consultant http://www.drgpcr.com/consulting/ - Share your feedback with us: http://www.drgpcr.com/audience-survey/ - Become a #DrGPCR Ecosystem Member http://www.drgpcr.com/membership/

For decades the pharmaceutical industry has synthesized millions of molecular entities in the pursuit of novel biological activities. These huge compound libraries have always been considered a treasure trove of potential new drugs for a plethora of new therapeutic targets. With the huge progress in laboratory automation and high-throughput technology over the last decade, library screening remains a key drug discovery strategy. The size of these libraries and their handling present however multiple challenges, starting from the synthesis and screening speed, storage space, and annotation required when working with Singleton compounds. A clever alternative finds inspiration from biology and leverages the DNA information storage power. This is known as DNA Encoded Libraries, or DELs. Dr. Katelyn Billings is a pioneer of this technology that offers a number of advantages, starting from the possibility of working on the nanoscale in as little as a few microliters to make and screen millions of molecules as a pool. In this episode we learn about how DELs work and discuss their advantages, challenges and the promise of combining data from DEL screens with machine learning to disrupt modern drug discovery.Visit https://thermofisher.com/bctl to register for your free Bringing Chemistry to Life T-shirt and https://www.alfa.com/en/chemistry-podcasts/ to access our episode summary sheet, which contains links to recent publications and additional content recommendations for our guest.

There is a constant discourse between herbalist and the scientific community...neither of which seem to see the side of another, but is there a place for herbalism within healing? Hosts Astra, Hanne, and Fel discuss what herbalism is and the place they feel is should occupy within the scientific world of drug development. What are the benefits and limitations of herbalism vs. synthetics? Fair warning, this episode goes deep into some science, but it's fascinating stuff!Come join our discord! https://discord.gg/kJthJyxTBcResources:Derivation of drugs from natural products (NPs) and current screening methods:The Story of Aspirin: https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14520NPs as a Source for Drug Design: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560124/Review of the role of NP in Drug Design: https://www.nature.com/articles/nrd1657A Historical Overview of NP in Drug Design: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901206/#B30-metabolites-02-00303NP in Drug Design: Advances and Opportunities: https://www.nature.com/articles/s41573-020-00114-zDried-leaf Artemesia annua: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323188/Whole Plan Artemesia annua as antimalarial therapy: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0052746Molecular Mechanism of Thalidomide: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281272/Psychedelics being re-engineered for clinical therapeutics: https://www.nature.com/articles/d41586-020-03404-zDrug Discovery ProcessStages of Drug Discovery: https://www.researchgate.net/publication/341097009Drug Discovery and Development - A story: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725284/

This Friday's special guest is my good friend @ronnieruyonga. Ronnie has a Ph.D in Pharmaceutical and Chemical Science, Organic Synthesis, Drug Design and Discovery. He pretty much works on formulating medicine and vaccines. Ronnie and I have been friends since highschool. He is currently based out of Santa Barbara, California. In this episode, we sit-down and virtually discuss about a variety of topics ranging from: his influences, what he does for a living. COVID -19 vaccine and much more. #LessonsLearnedATW #COVID19Vaccine #Medicine --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/lessonslearnedatw/support

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.11.20.391409v1?rss=1 Authors: Tempra, C., La Rosa, C., Lolicato, F. Abstract: The most accredited hypothesis links the toxicity of amyloid proteins to their harmful effects on membrane integrity through the formation of prefibrillar-transient oligomers able to disrupt cell membranes. However, damage mechanisms necessarily assume a first step in which the amyloidogenic protein transfers from the aqueous phase to the membrane hydrophobic core. This determinant step is still poorly understood. However, according to our lipid-chaperon hypothesis, free lipids in solution play a crucial role in facilitating this footfall. Free phospholipid concentration in the aqueous phase acts as a switch between ion channel-like pore and fibril formation, so that high free lipid concentration in solution promotes pore and repress fibril formation. Conversely, low free lipids in the solution favor fibril and repress pore formation. This behavior is due to the formation of stable lipid-protein complexes. Here, we hypothesize that the helix propensity is a fundamental requirement to fulfill the lipid-chaperon model. The alpha-helix region seems to be responsible for the binding with amphiphilic molecules fostering the proposed mechanism. Indeed, our results show the dependency of protein-lipid binding from the helical structure presence. When the helix content is substantially lower than the wild type, the contact probability decreases. Instead, if the helix is broadening, the contact probability increases. Our findings open a new perspective for in silico screening of secondary structure-targeting drugs of amyloidogenic proteins. Copy rights belong to original authors. Visit the link for more info

In this episode, Dr Kirsty Short talks to Professor Avril Robertson. Prof Robertson is a Professor in Biotechnology in the School of Chemistry and Molecular Biosciences at The University of Queensland. She completed a commercially focused degree and PhD in bio-organic chemistry at the University of St Andrews, Scotland in 2000. She also has qualifications in both secondary and tertiary teaching. Avril had a successful 10 years in the UK biotechnology and drug discovery industry before moving to The University of Queensland as Head of Medicinal Chemistry in the Center for Drug Design and Discovery in 2011. In 2017, she progressed to full Professor and Director of Biotechnology and also sits on the Board of Directors of the National Professional Science Masters Association in the USA.

How does an expert in pharmacokinetics, whose only exposure to computers was taking one semester of programming in college to meet a language requirement, become an advocate for the new AI-driven style of drug discovery? This week Harry finds out from Mark Eller, who helped to invent Allegra at Hoechst Marion Roussel (now Sanofi), spent 12 years at Jazz Pharmaceuticals, and is now senior vice president of research and development at twoXAR, an AI-driven drug discovery startup.In our previous episode from August 31, 2020, Harry spoke with twoXAR founder and CEO Andrew A. Radin, who confessed to being a computer nerd and lamented that it's been hard finding colleagues who are willing and able to help him bridge the gap between software and biology. He told the story of Mark Eller, who started out as a consultant at twoXAR but ended up telling Radin "I want you to offer me a job." Eller told Radin that the twoXAR project had finally convinced him that AI is good for more than just winning games of chess or Go, and that it can also be used to help drug developers predict which new molecules will be effective against specific diseases, even if their mechanisms of action are unfamiliar.  "He's gone from highly skeptical to highly supportive," says Radin. "I think that transformation is happening throughout the industry." This week, Harry gets the whole story of Eller's transformation, from Eller himself.How to rate MoneyBall Medicine on iTunes with an iPhone, iPad, or iPod touch:Launch the "Podcasts" app on your device. If you can't find this app, swipe all the way to the left on your home screen until you're on the Search page. Tap the search field at th top and type in "Podcasts." Apple's Podcasts app should show up in the search results.Tap the Podcasts app icon, and after it opens, tap the Search field at the top, or the little magnifying glass icon in the lower right corner.Type MoneyBall Medicine into the search field and press the Search button.In the search results, click on the MoneyBall Medicine logo.On the next page, scroll down until you see the Ratings & Reviews section. Below that you'll see five purple stars.Tap the stars to rate the show.Scroll down a little farther. You'll see a purple link saying "Write a Review."On the next screen, you'll see the stars again. You can tap them to leave a rating, if you haven't already.In the Title field, type a summary for your review.In the Review field, type your review.When you're finished, click Send.That's it, you're done. Thanks!

Dr Hannah Bruce Macdonald is a Research Fellow in the Chodera Lab at Memorial Sloan Kettering Cancer Center. Hannah researches free energy methods for applications in drug design. In this episode we discuss, how are free energy calculations used in drug discovery? And how important are computational methods for modern drug synthesis? Twitter - https://twitter.com/hannahbruce

This week Harry interviews Gregory Bowman, an associate professor in the department of biochemistry and molecular biophysics in the School of Medicine at Washington University in St. Louis. Bowman is the current director of Folding@home, a distributed computing project currently focused on analyzing the structures of coronavirus proteins to find targets for new drug therapies that could help end the pandemic.Understanding and modeling the 3D structures of tiny, ever-shifting protein molecules is a notoriously complex problem. Folding@home cuts through it by sending crystallography data and other information to thousands of home computers and using it to model possible protein configurations—effectively creating a large, networked supercomputer. The project has been underway in various forms since 2000, but has recently concentrated fully on the SARS-CoV-2 virus that causes covid-19. The hope is that the work will reveal locations on viral proteins where small-molecule drugs could bind, disrupting the virus's ability to enter human cells and replicate itself. By patching together so many distributed machines, "We are the first computer to reach the exascale," Bowman says. "Our peak performance is about 10-fold that of the world's fastest traditional supercomputer. Even before the 100-fold growth we have experienced since starting our work on covid-19, we were running calculations that would have cost millions of dollars to run on the cloud." Now that number is in the hundreds of millions of dollars. Anyone can contribute to the effort by going to foldingathome.org and downloading the Folding@home software to their Windows, Mac, or Linux machine.Please rate and review MoneyBall Medicine on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:• Launch the “Podcasts” app on your device. If you can’t find this app, swipe all the way to the left on your home screen until you’re on the Search page. Tap the search field at the top and type in “Podcasts.” Apple’s Podcasts app should show up in the search results.• Tap the Podcasts app icon, and after it opens, tap the Search field at the top, or the little magnifying glass icon in the lower right corner.• Type MoneyBall Medicine into the search field and press the Search button.• In the search results, click on the MoneyBall Medicine logo.• On the next page, scroll down until you see the Ratings & Reviews section. Below that, you’ll see five purple stars.• Tap the stars to rate the show.• Scroll down a little farther. You’ll see a purple link saying “Write a Review.”• On the next screen, you’ll see the stars again. You can tap them to leave a rating if you haven’t already.• In the Title field, type a summary for your review.• In the Review field, type your review.• When you’re finished, click Send.• That’s it, you’re done. Thanks!

Proteins are molecular machines that must first assemble themselves to function. But how does a protein, which is produced as a linear string of amino acids, assume the complex three-dimensional structure needed to carry out its job? That's where Folding at Home comes in. Folding at Home is a sophisticated computer program that simulates the way atoms push and pull on each other, applied to the problem of protein dynamics, aka "folding". These simulations help researchers understand protein function and to design drugs and antibodies to target them. Folding at Home is currently studying key proteins from the virus that causes COVID-19 to help therapeutic development. Given the extreme complexity of these simulations, they require an astronomical amount of compute power. Folding at Hold solves this problem with a distributed computing framework: it breaks up the calculations in the smaller pieces that can be run on independent computers. Users of Folding at Home - millions of them today - donate the spare compute power on their PCs to help run these simulations. This aggregate compute power represents the largest super computer in the world: currently 2.4 exaFLOPS!Folding at Home was launched 20 years ago this summer in the lab of Vijay Pande at Stanford. In this episode, Vijay (now a general partner at a16z) is joined by his former student and current director of Folding at Home, Greg Bowman, an associate professor at Washington University in St. Louis, and Lauren Richardson. We discuss the origins of the Folding at Home project along with its connection to SETI@Home and Napster; also the scientific and technical advances needed to solve the complex protein folding and distributed computing problems; and importantly what does understanding protein dynamics actually achieve? 

AI could create a streamlined, automated approach to drug discovery, trawling vast datasets to identify targets, find candidate molecules and predict synthesis routes. Getting there will require significant vision, but we are already seeing exciting examples of AI helping direct research and reduce discovery times. We discuss the short and long term potential of AI in drug discovery. By Dr Mark Roberts and Dr Sam Genway If you'd like to view the original article then follow the link below: https://www.ddw-online.com/informatics/p323284-how-artificial-intelligence-is-transforming-drug-design.html You can also download the original article pdf here: https://www.ddw-online.com/media/32/136775/(4)-how-artificial-intelligence.pdf For more information on Drug Discovery World, head to: https://www.ddw-online.com

Kelsey explains the questionable science behind using ketamine for treatment resistant depression. Spoiler alert: don't trust drugs that sound like miracle cures. References: CHAN, L. F., EU, C. L., SOH, S. Y., MANIAM, T., SHAHIDII KADIR, Z., CHONG, B. T. W., LOO, J. L., SHARIP, S., WONG, V. C. W., LOO, T. H., NG, Y. P., & KAHN, D. A. (2018). Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior. Journal of Psychiatric Practice, 24(4), 279–291. https://doi.org/10.1097/PRA.0000000000000316 Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology: Official Publication Of The American College Of Neuropsychopharmacology, 38(12), 2475–2483. https://doi.org/10.1038/npp.2013.150 Corriger A, & Pickering G. (2019). Ketamine and depression: a narrative review. Drug Design, Development and Therapy, 3051. Chen, J. (2019, March 21). How New Ketamine Drug Helps with Depression. Retrieved from https://www.yalemedicine.org/stories/ketamine-depression/ Meisner, R. C. (2019, May 20). Ketamine for major depression: New tool, new questions. Retrieved from https://www.health.harvard.edu/blog/ketamine-for-major-depression-new-tool-new-questions-2019052216673

For many, the term Artificial Intelligence (AI) is a phrase straight out of sci-fi, conjuring up visions of utopias or dystopias, from films ranging from the Terminator to I Robot. But what was previously sci-fi is now increasingly becoming reality. AI technology exists, and there's a brand new frontier where it's being applied to the world of healthcare. AI is helping to diagnose cancer, design new medicines, and even predict a person's medical future. In this programme, in partnership with Microsoft, we explore where AI technology is taking us... Like this podcast? Please help us by supporting the Naked Scientists

For many, the term Artificial Intelligence (AI) is a phrase straight out of sci-fi, conjuring up visions of utopias or dystopias, from films ranging from the Terminator to I Robot. But what was previously sci-fi is now increasingly becoming reality. AI technology exists, and there's a brand new frontier where it's being applied to the world of healthcare. AI is helping to diagnose cancer, design new medicines, and even predict a person's medical future. In this programme, in partnership with Microsoft, we explore where AI technology is taking us... Like this podcast? Please help us by supporting the Naked Scientists

Now a professor of biochemistry at the University of Cambridge, in 1969 Sir Thomas Blundell was one of the first people to see what the hormone insulin looked like. As part of the team led by Nobel Prize winner Dorothy Hodgkin, it was a medical breakthrough for diabetes patients everywhere. “I was always interested in doing a range of different things,” Professor Blundell says. “I came from a family where my grandfather was a very gifted artist and musician. And although my parents left school when they were 14 and 15, they always encouraged me to think more broadly.” “So I may be a little bit unusual because I've ended up doing things in politics, music and science, and that of course led me to advise prime ministers and to run organisations and found companies.” Professor Blundell's research has focussed on understanding the structure and function of molecules for targets to improve drug design. “By using X-rays with very short wavelength, I can see these very tiny molecules. Add in other methods like electron microscopy and the individual molecules can be revealed. His work has contributed significantly to stopping the progression of HIV into AIDS and to developing new drugs for cancer treatment in both his academic career and through a spinoff company he initially founded with two former students. “In Europe, Australia and the United States, we are lucky, we have access to medicines that research has developed, but the real challenge is to make sure that it's available not just to the rich, but to the world in general.” Episode recorded: September 26, 2019. Interviewer: Dr Andi Horvath. Producer, audio engineer and editor: Chris Hatzis. Co-production: Silvi Vann-Wall and Dr Andi Horvath. Image: Getty Images.

Now a professor of biochemistry at the University of Cambridge, in 1969 Sir Thomas Blundell was one of the first people to see what the hormone insulin looked like. As part of the team led by Nobel Prize winner Dorothy Hodgkin, it was a medical breakthrough for diabetes patients everywhere. “I was always interested in doing a range of different things,” Professor Blundell says. “I came from a family where my grandfather was a very gifted artist and musician. And although my parents left school when they were 14 and 15, they always encouraged me to think more broadly.” “So I may be a little bit unusual because I’ve ended up doing things in politics, music and science, and that of course led me to advise prime ministers and to run organisations and found companies.” Professor Blundell’s research has focussed on understanding the structure and function of molecules for targets to improve drug design. “By using X-rays with very short wavelength, I can see these very tiny molecules. Add in other methods like electron microscopy and the individual molecules can be revealed. His work has contributed significantly to stopping the progression of HIV into AIDS and to developing new drugs for cancer treatment in both his academic career and through a spinoff company he initially founded with two former students. “In Europe, Australia and the United States, we are lucky, we have access to medicines that research has developed, but the real challenge is to make sure that it’s available not just to the rich, but to the world in general.” Episode recorded: September 26, 2019. Interviewer: Dr Andi Horvath. Producer, audio engineer and editor: Chris Hatzis. Co-production: Silvi Vann-Wall and Dr Andi Horvath. Image: Getty Images.

On this week’s Tech Nation, Moira speaks with it’s all about data – who’s collecting it, and why, and how it can serve us, and maybe not. Lee Omar from Red Ninja talks about smart cities around the world, and the art of listening before you build. Tech Nation Health Chief Correspondent Daniel Kraft shows us we can crowdsource medical questions, while Tech Nation Regular Contributor Gary Davis reminds us that we love free stuff, and we pay for it with our data. Then Krishnan Nandabalan, the CEO of InveniAI sees continued value in the data used for drug approval after the drug is approved.

On this week’s Tech Nation, Moira speaks with it’s all about data – who’s collecting it, and why, and how it can serve us, and maybe not. Lee Omar from Red Ninja talks about smart cities around the world, and the art of listening before you build. Tech Nation Health Chief Correspondent Daniel Kraft shows us we can crowdsource medical questions, while Tech Nation Regular Contributor Gary Davis reminds us that we love free stuff, and we pay for it with our data. Then Krishnan Nandabalan, the CEO of InveniAI sees continued value in the data used for drug approval after the drug is approved.

In this episode, we take a closer look at deuteration, specifically involving the medication deutetrabenazine (discussed back in episode 76). We feature a guest contributor from our pharmacy sciences department who assists us as we look at the drug design aspects of this unique molecule and its implications for research moving forward.

Sarah Constantin is a mathematician & data scientist with a PhD from Yale. We discover how computer vision and machine learning can be used to do drug discovery what the biggest challenges in today's cancer research with potential solutions

In this podcast, we get to know Marcio van Muehlen, a biological engineer from MIT turned entrepreneur & product manager in Silicon Valley. He was working on cancer diagnostics through blood sampling and wanted to have better access to the work from other scientists in the field. There he recognized early on that we need a github for science and published a widely referenced article on it in 2011. We talk about why we need a github for science, what has happened since he wrote the article and what is still preventing us from having more open collaboration.

Benita Katzenellenbogen, John Katzenellenbogen, and Zeynep Madak-Erdogan explain how designer estrogens can deliver the the therapeutic benefits of natural estrogens with less cancer risk.

Description Not Provided.

In dieser Episode geht's um Wirkstoffforschung (auch genannt Drug Design), dem ersten Schritt der Medikamentenentwicklung. Unser Gast ist Bernd Rupp (ein Hörer!) vom Leibniz Institut für Molekulare Pharmakologie. Wir sprechen über Grundlagen und Begriffe, die Rolle der Wirkstoffforschung in der Medikamentenentwicklung, das prinzipielle Vorgehen sowie die Computerunterstützung.

CHI recently spoke with Dr. Chas Bountra, Head of the Structural Genomics Consortium (SGC), and Professor of Translational Medicine and an Associate Head of Medical Sciences at the University of Oxford. In this podcast, Dr. Bountra discusses how the SGC is impacting drug discovery and their work on developing novel probes, specifically for epigenetic targets. Dr. Bountra also gives a sneak peek into his keynote lecture joining the Structure-Based Drug Design and Chemical Biology for Target Validation meetings, May 22 in Boston.

Nandini Kashyap interviews Dr. Nicholas Meanwell, Executive Director of Department of Chemistry at Bristol-Myers Squibb Co. on March 25, 2014. Dr. Meanwell will be delivering keynote presentation during the 3rd Annual Property-Based Drug Design, May 22-23, 2014 at Westin Boston Waterfront Hotel in Boston, MA. Topics Include: Physicochemical properties in drug discovery and development, Bio-physical properties, Property based drug design, drug design, Solid State properties, Solubility, Permeability, Lipophilicity, Physicochemical descriptors, High-Throughput Physicochemical Screens, Developability of molecules, Polymorphism, Discovery workflow

This May 21-22 at the Structure-Based Drug Design conference in Boston, Dr. Jason Burch, a Medicinal Chemist at Genentech will give a talk on structure-based design and property optimization of potent and selective pyrazole carboxamide interleukin-2 inducible t-cell kinase (itk) inhibitors for the treatment of inflammatory diseases. CHI recently spoke with Dr. Burch about why he chose to pursue ITK inhibitors, important considerations for developing these types of inhibitors, and what techniques were used to improve pharmaceutical properties of the lead matter. Dr. Burch also discusses how advances in genomics and demand for personalized treatments has changed drug design techniques.

Dr. Compadre has extensive research experience, on the study of bioactive compounds from natural origin, and on the use of molecular modeling in drug design and structure-activity studies, with over 70 publications, 9 US patents related to the development of bioactive compounds, and one FDA approved antimicrobial technology. http://pharmcollege.uams.edu/departments-units/pharmaceutical-sciences/pharmaceutical-sciences-faculty/drccompadre/

There are several ways that the public can contribute to the world of scientific exploration. We talk to David Baker and Chris Eibens how the networked computer game 'Foldit' is contributing to the development of new medical drugs.

Have you considered the many varied and diverse career paths that are open to chemists and physicists? Learn how these pathways can lead you to a range of exciting careers from chemical and biotechnology industries to defence research that can take you anywhere in the world. Come and learn about photonics which is the science of ‘light’, using lasers and fibre optics. Photonics is seen as the latest, greatest and fastest growing industry in Australia, and predicted to produce around 18,000 new jobs by 2010. If you enjoy chemistry or physics, come along and find out about our six leading-edge named degrees: EcoChemistry; Molecular & Drug Design; Nanoscience & Materials; Space Science and Astrophysics, High Performance Computational Physics, and Optics and Photonics. Learn more about a BSc, majoring in chemistry and/or physics. The far reaches of the universe is the limit.

A challenge in drug design is the resistance that arises to drug therapy. Ideally, one would like to design a drug that is "promiscuous" enough to bind tightly to all potential mutants of its intended target. Mala's group studies the HIV system.

Prof. Graham Richards lectures at the Sutton Trust Chemistry Summer School, a week long workshop featuring chemistry lectures and lab work. The lectures cover a wide range of topics from Organic, Physical and Inorganic chemistries, given by members of the Oxford University Chemistry Department.

This course will assess the relationships among sequence, structure, and function in complex biological networks as well as progress in realistic modeling of quantitative, comprehensive, functional genomics analyses. Exercises will include algorithmic, statistical, database, and simulation approaches and practical applications to medicine, biotechnology, drug discovery, and genetic engineering. Future opportunities and current limitations will be critically addressed. In addition to the regular lecture sessions, supplementary sections are scheduled to address issues related to Perl, Mathematica and biology.

This course will assess the relationships among sequence, structure, and function in complex biological networks as well as progress in realistic modeling of quantitative, comprehensive, functional genomics analyses. Exercises will include algorithmic, statistical, database, and simulation approaches and practical applications to medicine, biotechnology, drug discovery, and genetic engineering. Future opportunities and current limitations will be critically addressed. In addition to the regular lecture sessions, supplementary sections are scheduled to address issues related to Perl, Mathematica and biology.

Más información de este acto